Description of Clinical Expertise

My clinical expertise spans both complex medical dermatology and health system innovation, with a focus on improving access, efficiency, and quality of care. I have led department-wide implementation of Epic-based triage and scheduling strategies that resulted in a ~77% reduction in new patient visit lead times and a substantial decrease in no-show rates, without increasing clinical capacity. These initiatives have been evaluated through peer-reviewed health systems research and have positioned our department among the highest-performing academic dermatology practices nationally for timely access.

In parallel, I have designed and implemented dermatology-specific electronic medical record tools that reduced documentation time and after-hours EMR use across a large cohort of clinicians while maintaining clinical productivity, with findings disseminated through peer-reviewed publication.

My clinical and research interests include chronic pruritus and prurigo nodularis, chronic idiopathic urticaria, atopic dermatitis, and psoriasis. I served as the lead investigator at my institution for the global phase 3 prurigo nodularis clinical trial evaluating dupilumab, which supported FDA approval for this indication; my site was the highest-enrolling center in the United States. This work reflects sustained engagement in late-phase clinical trials that directly inform regulatory approval and standards of care.

I am also actively engaged in research evaluating AI-based dermatology triage and scheduling modalities, including clinical decision support tools designed to improve risk stratification and access to timely care. In addition, I am investigating a novel non-invasive, AI-enabled skin lesion assessment device developed by Veriskin, Inc., aimed at supporting primary care clinicians in more efficiently triaging concerning skin lesions for specialist referral.

I have collaborated closely with pharmacy leadership to develop standardized therapeutic interchange protocols for commonly prescribed dermatologic medications for Medicaid patients, resulting in reduced prior authorization denials, shorter time to treatment, expanded access through medication delivery options, and improved prescription retention within the health system. I have also been invited to speak nationally on dermatology access, operational innovation, and implementation of 340B drug pricing programs within academic health systems.